Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents
MALVERN, Pa., May 15, 2024 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders announced today that Humana has become the first commercial payer to update its policy in response to the Company’s recent clearance from the U.S. Food and Drug Administration (FDA) for NeuroStar TMS (transcranial magnetic stimulation) as a first-line add-on for adolescents aged 15-21 with MDD (major depressive disorder).